Glepaglutide for short bowel syndrome

Many people with short bowel syndrome (SBS) are dependent on frequent administration of intravenous fluids and nutrition delivered through a central catheter (so-called total parenteral nutrition or TPN). As such, they are at risk for a number of serious and life-threatening complications associated with their disease and treatment, including risk of sepsis and other infections, blood clots, liver damage and renal impairment and shortened life expectancy.

Glepaglutide is a long-acting GLP-2 analog in development for the treatment of SBS. It was granted orphan drug designation by the U.S. FDA and is currently being studied in Phase 3 clinical trials. For more information, see (identifier: NCT03690206)

Glepaglutide is an investigational candidate, not yet approved by the U.S. Food & Drug Administration (“FDA”) for short bowel syndrome, and the safety and effectiveness of glepaglutide has not yet been established.